Post hoc data in the SELECT trial
Post hoc data
Duration of response analysis
30-month (95% CI: 18.4-36.7) median duration of response among patients who responded to LENVIMA1
- Post hoc analysis (n=261) was conducted based on investigator-assessed response; 157 patients (60.2%) in the LENVIMA arm responded per investigator assessment1
Limitations: The post hoc exploratory subgroup analysis (data cutoff: September 1, 2016) was not a prespecified study endpoint. Patients who did not respond were not evaluated. No conclusions can be drawn.
SELECT=Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid.
Post hoc data
Median time to first objective response2
2.0-month (95% Cl: 1.9-3.5) median time to first objective response among patients who responded in the LENVIMA arm and 5.6 months (95% Cl: 1.8-9.4) among patients who responded in the placebo arm:
- Analysis was conducted based on independent radiologic review of response: 169 patients (n=261; 65%) in the LENVIMA arm and 2 patients (n=131; 2%) in the placebo arm responded to treatment
- Tumor assessments using RECIST version 1.1 were performed every 8 weeks following randomization
Limitations: The exploratory subgroup analysis (data cutoff: November 15, 2013) was not a prespecified study endpoint. The outcomes of this analysis cannot be compared across treatment groups. Patients who did not respond were not evaluated. No conclusions can be drawn.
RECIST=Response Evaluation Criteria In Solid Tumors.